3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Pancreatic Neoplasms
11
Colorectal Neoplasms
10
Neoplasm Metastasis
6
Rhabdomyosarcoma
3
Neuroblastoma
3
Lung Neoplasms
3
Cholangiocarcinoma
3
Biliary Tract Neoplasms
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma, Ewing
2
Sarcoma
2
Rectal Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Neuroendocrine
2
Uterine Cervical Neoplasms
1
Solid Tumors
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Refractory Solid Tumors
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Medulloblastoma
1
Malignant mesenchymal tumor
1
Intestinal Neoplasms
1
Gastrointestinal Neoplasms
1
Interventions
enzalutamide
21
Magnetic Resonance Spectroscopy
21
apalutamide
17
Androgen Antagonists
14
Specimen Handling
13
Prednisone
13
Abiraterone Acetate
13
abiraterone
9
Docetaxel
9
Radiotherapy
8
Biopsy
8
darolutamide
7
Radiosurgery
7
Pluvicto
7
Nivolumab
7
cabazitaxel
6
Lutetium-177
6
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
6
Lutetium
5
radium Ra 223 dichloride
4
pembrolizumab
4
niraparib
4
gallium 68 PSMA-11
4
cabozantinib
4
bicalutamide
4
atezolizumab
4
Watchful Waiting
4
Surveys and Questionnaires
4
Standard of Care
4
Radiotherapy, Intensity-Modulated
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Irinotecan
×
30 days
×
Clear all
No trials found.